These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 28301216)

  • 1. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
    L'Hermite M
    Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Cobin RH; Goodman NF;
    Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and benefit considerations for menopausal hormone therapy.
    Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
    Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
    Canonico M
    Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of micronized progesterone on breast cancer risk: a systematic review.
    Stute P; Wildt L; Neulen J
    Climacteric; 2018 Apr; 21(2):111-122. PubMed ID: 29384406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
    Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
    Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
    Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
    Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence.
    Prior JC
    Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):495-501. PubMed ID: 26512775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
    Simon JA
    Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.
    Miller VM; Taylor HS; Naftolin F; Manson JE; Gleason CE; Brinton EA; Kling JM; Cedars MI; Dowling NM; Kantarci K; Harman SM
    Climacteric; 2021 Apr; 24(2):139-145. PubMed ID: 32880220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
    Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
    JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins.
    Graham S; Archer DF; Simon JA; Ohleth KM; Bernick B
    Gynecol Endocrinol; 2022 Nov; 38(11):891-910. PubMed ID: 36075250
    [No Abstract]   [Full Text] [Related]  

  • 18. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.
    Gompel A
    Climacteric; 2018 Aug; 21(4):321-325. PubMed ID: 29583028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
    Shufelt CL; Manson JE
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1245-1254. PubMed ID: 33506261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?
    Simon JA
    Menopause; 2014 Jul; 21(7):769-83. PubMed ID: 24398406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.